Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Articles
Articles
EXTENTORCH Trial Results of First-Line Toripalimab Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC
ESMO 2023 - Small Cell Lung Cancer
The randomized, placebo-controlled, phase 3 EXTENTORCH trial (NCT04012606) assessed the clinical efficacy and safety of the anti–PD-1 antibody toripalimab in combination with etoposide plus platinum-based chemotherapy for the first-line treatment of patients with extended-stage SCLC (ES-SCLC); initial results of this study, presented at the 2023 ESMO annual meeting, are summarized here.
Read More ›
Phase 2 DeLLphi-301 Study Results of Tarlatamab in Previously Treated SCLC
ESMO 2023 - Small Cell Lung Cancer
New immunotherapeutic approaches are being investigated in small cell lung cancer (SCLC). Tarlatamab is a bispecific T-cell engager that binds to both delta-like ligand 3 (DLL3) on SCLC cells and CD3 on T cells to elicit T-cell–mediated tumor lysis.
Read More ›
Anti-HER2/HER3 αDC1 Vaccines Plus Pembrolizumab for Brain Metastasis in Triple-Negative or HER2-Positive BC
ASCO 2023 - Breast Cancer
An ongoing phase 2 study is evaluating HER2/HER3-directed dendritic cell vaccines combined with pembrolizumab in patients with brain metastasis from triple-negative breast cancer or HER2-positive breast cancer.
Read More ›
Neoadjuvant Intratumoral Dendritic Cell Vaccine Therapy Plus Paclitaxel, Trastuzumab, and Pertuzumab in HER2-Positive BC
ASCO 2023 - Breast Cancer
Preliminary results of the phase 2 NATASHA trial showed that neoadjuvant HER2-directed intratumoral dendritic cell vaccine therapy followed by paclitaxel, trastuzumab, and pertuzumab was well-tolerated in patients with HER2-positive breast cancer.
Read More ›
Phase 1b/2 Trial of Ribociclib, Tucatinib, and Trastuzumab for HER2-Positive BC
ASCO 2023 - Breast Cancer
The phase 1b/2 UCLA B-13 trial is evaluating the safety and efficacy of HER2 tyrosine kinase inhibitor tucatinib plus the cyclin-dependent kinase 4/6 inhibitor ribociclib and trastuzumab in the neoadjuvant setting for the treatment of patients with HER2-positive breast cancer.
Read More ›
Dalpiciclib Combined With Pyrotinib and Endocrine Therapy in Dual Receptor–Positive (ER-Positive/HER2-Positive) MBC
ASCO 2023 - Breast Cancer
Results of the phase 2 PLEASURABLE study indicated that the chemotherapy-sparing regimen of dalpiciclib combined with pyrotinib and endocrine therapy showed significant antitumor activity for patients with estrogen receptor–positive/HER2-positive metastatic breast cancer in the front-line setting.
Read More ›
Preclinical and Early Clinical Data of the HER2 Inhibitor ZN-1041 in Patients With BC With Brain Metastases
ASCO 2023 - Breast Cancer
Promising safety and antitumor activity data were obtained with the HER2 inhibitor ZN-1041, which is specifically designed to cross the blood-brain barrier, in preclinical and phase 1 studies in patients with HER2-positive breast cancer with brain metastases.
Read More ›
First-Line Zanidatamab Plus Docetaxel in Advanced HER2-Positive BC
ASCO 2023 - Breast Cancer
Updated results of a phase 1b/2 trial showed that zanidatamab plus docetaxel as first-line therapy had a manageable safety profile and demonstrated promising antitumor activity in patients with advanced HER2-positive breast cancer.
Read More ›
Real-World Treatment Patterns of Tucatinib Therapy in HER2-Positive MBC
ASCO 2023 - Breast Cancer
Real-world data from a US claims database reported similar efficacy as from a previous clinical trial in patients with previously treated HER2-positive metastatic breast cancer.
Read More ›
Anti-HER2 Antibody Inetetamab Plus Camrelizumab and Utidelone for Pretreated HER2-Positive MBC
ASCO 2023 - Breast Cancer
Final results of the phase 2 ICU trial confirmed earlier reports of promising efficacy and acceptable safety of anti-HER2 antibody inetetamab in combination with camrelizumab and utidelone in patients with pretreated HER2-positive metastatic breast cancer.
Read More ›
Page 6 of 136
3
4
5
6
7
8
9
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us